[{"id":"20ef9c7a-270b-4334-ae3f-5250c38786e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05768035","created_at":"2023-03-14T14:01:45.248Z","updated_at":"2024-07-02T16:35:35.814Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide","source_id_and_acronym":"NCT05768035","lead_sponsor":"Smart Immune SAS","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • SMART 101"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/06/2023","start_date":" 06/06/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-09-25"},{"id":"b43762fe-b14c-4dfa-9bac-1d1126ba8d4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04959903","created_at":"2021-07-13T12:53:28.837Z","updated_at":"2024-07-02T16:35:54.013Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT","source_id_and_acronym":"NCT04959903","lead_sponsor":"Smart Immune SAS","biomarkers":" TP53 • CD4","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMART 101"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/31/2022","start_date":" 03/31/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2023-03-06"}]